Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment

Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment

Abstract Chronic hepatitis C (CHC) is a major cause of cirrhosis, hepatocellular carcinoma (HCC), and mortality. Eliminating hepatitis C virus (HCV) can greatly improve long‐term outcomes. Several direct‐acting antiviral agents (DAAs), including sofosbuvir (SOF) plus different NS5A inhibitors, as we...

Full description

Bibliographic Details
Main Authors: Tzu‐Sheng Cheng, Po‐Cheng Liang, Chung‐Feng Huang, Ming‐Lun Yeh, Ching‐I Huang, Zu‐Yau Lin, Shinn‐Cherng Chen, Jee‐Fu Huang, Chia‐Yen Dai, Ping‐Hsin Hsieh, Wan‐Long Chuang, Ming‐Lung Yu
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Kaohsiung Journal of Medical Sciences
Subjects:
chronic hepatitis C
DAAs
genotype 2
HCV
Taiwan
Online Access:https://doi.org/10.1002/kjm2.12315

Internet

https://doi.org/10.1002/kjm2.12315

Similar Items